In September 2024, we announced a 340B rebate model for STELARA and XARELTO, aiming to enhance program transparency and integrity by validating that covered entities have purchased and dispensed these medicines. The model involves hospitals purchasing the drugs at standard prices and receiving rebates within 7-10 days of submitting standard dispensing data, ensuring timely reimbursement and adherence to 340B program requirements.
View the full letter here.